Sorrento Therapeutics(GB:0L85)
$0.020.00 (0.00%)
GB:0L85
Sorrento Therapeutics financials statements
$0.02
At close:0.00 (0.00%)
Sorrento Therapeutics (0L85) Income Statement
2 Followers
Sorrento Therapeutics Income Statement
Last quarter (Q2 2023), Sorrento Therapeutics's total revenue was $15.03M, an increase of 31.10% from the same quarter last year. In Q2, Sorrento Therapeutics's net income was $-95.21M. See Sorrento Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| $ 62.84M | $ 52.90M | $ 39.99M | $ 31.43M | $ 21.19M | |
| $ 29.39M | $ 39.87M | $ 30.05M | $ 19.20M | $ 11.12M | |
| $ 533.70M | $ 407.92M | $ 231.57M | $ 214.38M | $ 140.60M | |
| Depreciation and Amortization | $ 13.24M | $ 12.46M | $ 11.01M | $ 10.99M | $ 9.05M |
| $ -539.93M | $ -439.84M | $ -279.42M | $ -313.54M | $ -147.10M | |
| $ -504.31M | $ -368.05M | $ -201.53M | $ -195.18M | $ -129.48M | |
| $ -57.43M | $ -94.48M | $ -114.90M | $ -100.18M | $ -63.36M | |
| $ -561.75M | $ -462.53M | $ -316.42M | $ -359.58M | $ -213.78M | |
| $ -572.84M | $ -429.01M | $ -298.46M | $ -359.10M | $ -203.54M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.37 | $ -1.46 | $ -1.30 | $ -2.56 | $ -1.92 |
| Diluted EPS | $ -1.37 | $ -1.46 | $ -1.30 | $ -2.56 | $ -1.92 |
| Weighted Average Shares Outstanding | 419.31M | 294.77M | 229.82M | 140.51M | 106.15M |
| Weighted Average Shares Outstanding (Diluted) | 419.31M | 294.77M | 229.82M | 140.51M | 106.15M |
Currency in USD

